BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30714167)

  • 21. Evaluation of circulating EBV microRNA BART2-5p in facilitating early detection and screening of nasopharyngeal carcinoma.
    Jiang C; Chen J; Xie S; Zhang L; Xiang Y; Lung M; Kam NW; Kwong DL; Cao S; Guan XY
    Int J Cancer; 2018 Dec; 143(12):3209-3217. PubMed ID: 29971780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantification of Epstein-Barr virus DNA load, interleukin-6, interleukin-10, transforming growth factor-beta1 and stem cell factor in plasma of patients with nasopharyngeal carcinoma.
    Tan EL; Selvaratnam G; Kananathan R; Sam CK
    BMC Cancer; 2006 Sep; 6():227. PubMed ID: 16995954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
    Zheng XH; Lu LX; Li XZ; Jia WH
    Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Application of circulating plasma/serum EBV DNA in the clinical management of nasopharyngeal carcinoma.
    Yip TT; Ngan RK; Fong AH; Law SC
    Oral Oncol; 2014 Jun; 50(6):527-38. PubMed ID: 24440146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiplex Epstein-Barr virus BALF2 genotyping detects high-risk variants in plasma for population screening of nasopharyngeal carcinoma.
    Miller JA; Sahoo MK; Yamamoto F; Huang C; Wang H; Zehnder JL; Le QT; Pinsky BA
    Mol Cancer; 2022 Jul; 21(1):154. PubMed ID: 35902864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Quantitative analysis of plasma Epstein-Barr virus (EBV) DNA for monitoring of recurrence and metastasis in nasopharyngeal carcinoma patients after radiotherapy].
    Li YH; Shao JY; Zhao MQ; Gao HY; Li LR; Guan ZZ; Zeng YX
    Ai Zheng; 2003 Jun; 22(6):645-8. PubMed ID: 12948418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type.
    Leung SF; Chan AT; Zee B; Ma B; Chan LY; Johnson PJ; Lo YM
    Cancer; 2003 Jul; 98(2):288-91. PubMed ID: 12872347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody.
    Leung SF; Tam JS; Chan AT; Zee B; Chan LY; Huang DP; Van Hasselt A; Johnson PJ; Lo YM
    Clin Chem; 2004 Feb; 50(2):339-45. PubMed ID: 14684618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
    Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
    Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vesicle-bound EBV-BART13-3p miRNA in circulation distinguishes nasopharyngeal from other head and neck cancer and asymptomatic EBV-infections.
    Ramayanti O; Verkuijlen SAWM; Novianti P; Scheepbouwer C; Misovic B; Koppers-Lalic D; van Weering J; Beckers L; Adham M; Martorelli D; Middeldorp JM; Pegtel DM
    Int J Cancer; 2019 May; 144(10):2555-2566. PubMed ID: 30411781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
    Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
    Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of plasma Epstein-Barr virus DNA load as a prognostic marker for nasopharyngeal carcinoma.
    Tan EL; Looi LM; Sam CK
    Singapore Med J; 2006 Sep; 47(9):803-7. PubMed ID: 16924363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum/plasma viral DNA: mechanisms and diagnostic applications to nasopharyngeal and cervical carcinoma.
    Mutirangura A
    Ann N Y Acad Sci; 2001 Sep; 945():59-67. PubMed ID: 11708495
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of plasma Epstein-Barr virus DNA in the management of recurrent nasopharyngeal carcinoma.
    Chan JY; Wong ST
    Laryngoscope; 2014 Jan; 124(1):126-30. PubMed ID: 23686740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-sensitivity C-reactive protein complements plasma Epstein-Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort study.
    Tang LQ; Li CF; Chen QY; Zhang L; Lai XP; He Y; Xu YX; Hu DP; Wen SH; Peng YT; Chen WH; Liu H; Guo SS; Liu LT; Li J; Zhang JP; Guo L; Zhao C; Cao KJ; Qian CN; Zeng YX; Guo X; Mai HQ; Zeng MS
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):325-36. PubMed ID: 25482300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients.
    Kim KY; Le QT; Yom SS; Ng RHW; Chan KCA; Bratman SV; Welch JJ; Divi RL; Petryshyn RA; Conley BA
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):996-1001. PubMed ID: 28721913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic implication of pretreatment plasma/serum concentration of Epstein-Barr virus DNA in nasopharyngeal carcinoma.
    Lo YM
    Biomed Pharmacother; 2001 Sep; 55(7):362-5. PubMed ID: 11669497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
    Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
    Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of clinical and molecular surveillance in patients with advanced nasopharyngeal carcinoma after primary therapy: the potential role of quantitative analysis of circulating Epstein-Barr virus DNA.
    Hong RL; Lin CY; Ting LL; Ko JY; Hsu MM
    Cancer; 2004 Apr; 100(7):1429-37. PubMed ID: 15042677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nasopharyngeal Epstein-Barr Virus Load: An Efficient Supplementary Method for Population-Based Nasopharyngeal Carcinoma Screening.
    Chen Y; Zhao W; Lin L; Xiao X; Zhou X; Ming H; Huang T; Liao J; Li Y; Zeng X; Huang G; Ye W; Zhang Z
    PLoS One; 2015; 10(7):e0132669. PubMed ID: 26151639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.